Navigation Links
Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
Date:4/21/2009

NEW YORK, April 21 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. The full 56-page report can be found at www.crystalra.com.

ACT Biotech, Inc. ("ACT Biotech" or "the Company") is a closely held pharmaceutical company focused exclusively on the development and commercialization of novel cancer therapeutics. Following a technology spinout from Bayer HealthCare LLC, ACT Biotech was founded with worldwide rights to a portfolio of in-licensed compounds that now compose four oncology programs. Each program demonstrates activity against a different set of molecular targets--including several kinases that are associated with cancer cell communication and growth--in order to inhibit various signaling pathways that are important in tumor development.

The Company's lead candidate, Telatinib, is a potent and highly selective oral tyrosine kinase inhibitor compound that targets pathways associated with the formation of tumor-related blood vessels (angiogenesis). While ACT Biotech has selected gastric (stomach) cancer as Telatinib's lead clinical target, the agent has also demonstrated solid potential as a drug candidate to treat colorectal, liver, and kidney cancers. In addition, based on its ability to readily combine at full dose with various standard-of-care chemotherapy regimens, Telatinib may have expansion opportunity to treat other major cancers, such as lung, breast, and prostate cancers. Gastric cancer is the second leading cause of cancer-related death worldwide with approximately 800,000 fatalities in 2007. It is also the fourth most common cancer, with over one million new cases diagnosed in 2007. The Company aims to initially develop Telatinib in two indications, gastric and colorectal cancer, with patient enrollment for a Phase II trial set to begin during the second quarter 2009.

ACT Biotech's second product candidate is the Multi-Mode Kinase Inhibitor (ACTB1003), an oral anticancer compound that works via several mechanisms of action: (1) targeting select kinases that are altered in human cancers; (2) inhibiting angiogenesis; and (3) inducing apoptosis (programmed cell death). When evaluated against other oral, commercially available, targeted agents, ACTB1003 demonstrated greater anti-tumor activity in vivo. The compound may have utility in several major indications, including non-small cell lung cancer, breast cancer, colorectal cancer, multiple myeloma, bladder cancer, and melanoma. The Company intends to file an Investigational New Drug (IND) application for ACTB1003 and to commence clinical testing during 2009.

ACT Biotech, which was founded in early 2008, is currently following a three-year operating plan during which it intends to pursue various strategic alliances. The Company is headquartered in San Francisco, California.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal-clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars for its services in creating and updating the base report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Physicists discover important step for making light crystals
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
3. New imaging technique reveals the atomic structure of nanocrystals
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
5. Avantium Launches the Crystalline, a New Parallel System for Crystallization Research
6. ScinoPharm Granted US Patent for Novel Crystal Forms
7. Vermont Surgeon Implants First Accommodating Crystalens in Russia
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
9. SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides
10. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Insights, 2016", report provides in depth insights ... activities around the Protein-Tyrosine Phosphatase 1B (PTP1B) ... profiles in various stages of development including ... Phase III and Preregistration. Report covers the ...
(Date:2/8/2016)... N.C. , Feb. 8, 2016 Novan, Inc. today ... Chairman of the Board of Directors of Novan. In addition, ... North Carolina . --> ... Company also announced that it received a total of $32.8 million ... 2015 from its private investor network originating throughout the Research Triangle ...
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. , an ... technology, today announced the availability of AllegroGraph 6, the leading Semantic Graph Database ... Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph Database to ...
Breaking Biology Technology:
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):